Skip to main content
Premium Trial:

Request an Annual Quote

BioReference Laboratories Cites GeneDx Contribution to Revenue Growth

NEW YORK (GenomeWeb News) – BioReference Laboratories, an Elmwood Park, NJ-based clinical lab firm, today reported that its fiscal third quarter revenues increased 16 percent year over year and cited strong growth for its GeneDx subsidiary.

BRL reported total revenues of $185.4 million for the three months ended July 31, up from $160.5 million for the third quarter of 2012. It beat the consensus Wall Street estimate of $183.5 million. The firm had reported revenues of $172.3 million for Q3 last year, but that result has been adjusted in accordance with an accounting standards update, it said.

BRL posted net income of $14.7 million, or $.53 per share, for the quarter, compared to $12.6 million, or $.45 per share, for Q3 2012. It surpassed analysts' consensus estimate of $.51.

"Our performance in the third quarter was quite similar to the results we reported in the immediately preceding second quarter: growth in all elements of our business but especially strong in our genetics area through GeneDx," BRL CEO Marc Grodman said in a statement.

The firm, however, didn't break out specific sales figures for GeneDx, a diagnostic genetic sequencing lab.

Last week, BRL said that GeneDx will acquire Edge Biosystems' genetic sequencing service business, Edge BioServ, which provides sequencing services in a CLIA certified laboratory.

"We have new lines of specialty work being developed, including our upcoming inherited cancers and tumor sequencing programs that we believe will be in great demand. The Edge BioServ acquisition is expected to enable us to seamlessly meet those demands," Grodman said at the time of the acquisition announcement.

In addition, earlier this week, GeneDx launched its next-gen sequencing inherited cancer tests, including panels that incorporate the BRCA 1 and 2 genes.

BRL finished the quarter with $28.6 million in cash and cash equivalents.

In Thursday trade on the Nasdaq, shares of BRL closed up 4 percent at $29.15.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.